showed a trendp = 0.089
Patients harboring a KRAS mutation showed a statistically significant lower OR for platinum sensitive disease (OR = 0.72 [95% CI, 0.56–0.92], p = 0.010), and patients with CCNE1 amplifications showed a trend for a statistically significant lower OR for platinum sensitive disease (OR = 0.84 [95% CI, 0.68–1.03], p = 0.089).